AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00800787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nabi-HB
Description: Hepatitis b Immune Globulin (Human)(Nabi-HB) 312 IU/L per dose administered subcutaneously.~Dosage will be according to each patients body weight, as follow:~\< 75 kg: 500 IU weekly ( may be increase to 1,000 IU weekly if anti-HBs levels are \<150 IU/ML > 75 Kg: 1,000 IU weekly
Study NCT00762749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine HCl
Description: A single liquid dose of diphenhydramine HCl (12.5 mg /5 mL) followed by water, according to an age-weight dosing schedule
Study NCT02094833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP~T combined vaccine
Description: 0.5 mL, Intramuscular
Study NCT02094833 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV//PRP~T and Hepatitis B vaccine
Description: 0.5 mL, Intramuscular
Study NCT00578786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ambrisentan
Description: 2.5, 5.0 or 10.0 mg ambrisentan po, qd, long-term
Study NCT00162890 — intervention group
Intervention type: BEHAVIORAL
Intervention: Therapeutic exercise
Study NCT03463733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: 147-94-4/HYDROXYCARBAMIDE/HYDROXYCARBAMIDE/based on myeloproliferative disorders (MPD) record: SUB08076MIG
Study NCT03463733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 85622-93-1 /TEMOZOLOMIDE/TEMOZOLOMIDE/based on myeloproliferative disorders (MPD) record: SUB10889MIG
Study NCT06226831 — intervention group
Intervention type: OTHER
Intervention: Structured interview
Description: In-person structured interviews will be performed by the investigators.
Study NCT00913250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serum containing Avonex
Description: 60mcg IM dose of serum containing Avonex on Day 1, followed by 60mcg IM dose of serum free Avonex on Day 15
Study NCT00913250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serum Free Avonex
Description: 60mcg IM dose of serum free Avonex on Day 1, followed by 60mcg IM dose of serum containing Avonex on Day 15.
Study NCT03558022 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt Pills
Description: 7 days of a low sodium diet plus 4 salt pills (sodium chloride) taken 3 times daily with meals (approximately 7000 milligrams per day)
Study NCT03558022 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pills
Description: 7 days of low sodium diet plus 4 placebo pills (microcrystalline cellulose) taken 3 times daily with meals
Study NCT02923089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muffin: 25g available carbohydrate from small green lentil
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
Study NCT02923089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muffin: 25g available carbohydrate from split red lentil
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
Study NCT02923089 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wheat muffin
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
Study NCT02923089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soup: 25g available carbohydrate from small green lentil
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
Study NCT02923089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soup: 25g available carbohydrate from split red lentil
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
Study NCT02923089 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Potato soup
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
Study NCT02923089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chili: 25g available carbohydrate from small green lentil
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
Study NCT02923089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chili: 25g available carbohydrate from split red lentil
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
Study NCT02923089 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rice chili
Description: Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
Study NCT02653300 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Insulin
Description: all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.
Study NCT00204971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral glutamine powder
Description: nutritional supplement
Study NCT00204971 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo control
Study NCT00328822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Study NCT00328822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00626210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: 100-400 mg daily for 4 weeks
Study NCT04047693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose dense MVAC with pegylated GCSF
Description: Methotrexate, 30 mg/m2 IV bolus, Day 1 Vinblastine, 3 mg/m2 IV bolus, Day2 Doxorubicin, 30 mg/m2 IV bolus, Day2 Cisplatin, 70 mg/m2 IV over 1hr, Day2 Pegylated G-CSF, 6mg SC, Day 3 every 2 weeks
Study NCT03417518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane Inhalant Product
Description: General anesthesia will be induced with sufentanyl (0.2µg/kg) and thiopental (5mg/kg) and maintained by desflurane
Study NCT03417518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: General anesthesia will be induced with propofol (2mg/kg) and sufentanyl (0.2µg/kg) and maintained by propofol in a target-controlled infusion mode
Study NCT00497601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B fat emulsion in visceral leishmaniasis
Description: Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 \& 3 in group A Amphotericin B in fat emulsion (Amphomul) 10 \& 5 mg/kg on day 1 \& 3 in group B Amphotericin B in fat emulsion (Amphomul) 12.5 \& 2.5 mg/kg on day 1 \& 3 in group C Amphotericin B in fat emulsion (Amphomul) 15 mg/kg on day 1 in group D
Study NCT00497601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B fat emulsion
Description: Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
Study NCT00497601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B in fat emulsion
Description: Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
Study NCT03558256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy
Description: Patients participating in the experimental group will receive the MBCT intervention besides the usual medication treatment. The intervention is implemented by the manual adapted from the MBCT for Depression (Segal et al. 2013). The modified version of the program has the same structure with the original manual combined the mindfulness training and the cognitive elements from CBT, but the content is more suitable for the Chinese. The instructors in this study are trained and certificated psychiatrists and psychotherapists with rich experience of working with MDD, and they will receive a weekly supervision conducted by a senior supervisor.
Study NCT03558256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication
Description: Both of the MBCT group and the medication group will receive the medication treatment. The initial dose conforms the drug instructions, the dosage can be adjusted once a week, and the maximum dosage should not exceed the maximum amount by the instructions. MDD patients with sleep disorders can use drugs combined with benzodiazepine drugs, but not continuing for more than two weeks; while other psychotropic drugs are not allowed. All of the drugs used in this study are usual clinical drugs with good security, the common adverse reactions include nausea, dry mouth, constipation, diarrhea, indigestion, dizziness, drowsiness, fatigue, sweating, heart palpitations, delayed ejaculation in male, increasing blood aminotransferase without symptoms occasionally and so on.
Study NCT03558256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication
Description: Both of the MBCT group and the medication group will receive the medication treatment. The initial dose conforms the drug instructions, the dosage can be adjusted once a week, and the maximum dosage should not exceed the maximum amount by the instructions. MDD patients with sleep disorders can use drugs combined with benzodiazepine drugs, but not continuing for more than two weeks; while other psychotropic drugs are not allowed. All of the drugs used in this study are usual clinical drugs with good security, the common adverse reactions include nausea, dry mouth, constipation, diarrhea, indigestion, dizziness, drowsiness, fatigue, sweating, heart palpitations, delayed ejaculation in male, increasing blood aminotransferase without symptoms occasionally and so on.
Study NCT00446238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: CBT enhanced with physical illness narrative, family education, and social skills components.
Study NCT00446238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Community Care Treatment
Description: Treatment as usual for depression and related symptoms provided within the community.
Study NCT03651583 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Kiko exercises-combines breathing and movement
Study NCT04460014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple cognitive task intervention
Description: Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory.
Study NCT04460014 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Placebo
Description: Session 1: Digital activity for same amount of time (e.g. listening to podcast on own smartphone).
Study NCT01306422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hoodia gordonii purified extract (H.g.PE)
Description: H.g.PE(1110 mg) formulated yogurt drink, twice-daily, 65 minutes before breakfast and dinner, for 15 days
Study NCT01306422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo yogurt drink
Description: Placebo product (yogurt drink matching the H.g.PE extract formulated yogurt drink in nutritional composition and taste. Placebo is consumed twice-daily, 65 minutes before breakfast and dinner for 15 days.
Study NCT01306422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo yogurt drink
Description: Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
Study NCT01306422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo yogurt drink
Description: Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
Study NCT01306422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hoodia gordonii purified extract (H.g.PE)
Description: H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
Study NCT01306422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hoodia gordonii purified extract (H.g.PE)
Description: H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
Study NCT03788395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler plus Turbo+
Description: Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) plus Turbo+ for three months.
Study NCT03788395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbohaler without Turbo+
Description: Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) without Turbo+ for three months.
Study NCT01605981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMN107
Study NCT04194853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyographic Biofeedback
Description: Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength .Electromyographic (EMG) biofeedback is a specific form of biofeedback. The biofeedback device records muscle activity through the application of electrodes superficially or subcutaneously when targeting specific muscles
Study NCT04194853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadriceps Isometric exercises
Description: In supine lying or sitting, Patient is asked to press down knee while contracting Quadriceps muscles.
Study NCT00108069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen citrate
Description: oral dose 120 mg twice a day, every day
Study NCT00108069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: intravenous (IV) injection 1.3 mg/m\^2 days 3, 6, 10, 13, 24, 27,31,34 on every 6 week cycle
Study NCT01983397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent training
Description: The multicomponent training consisted of individuals subjected to a multicomponent exercise program: 5 minute warm up, 20 minutes of aerobic exercise, 15-20 minutes of strength exercises, 10 minutes of coordination, agility and balance exercises and 5 minute of cool-down.
Study NCT01983397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: The resistance training was subjected to a strength training using weight machines adapted for elderly. The protocol followed three sets of 10 to 12 maximal repetitions, moderate speed (two seconds for the shortening phase and three seconds for the elongation phase) and one minute for rest interval between sets.
Study NCT01612143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: setrobuvir
Description: 200 mg capsule formulation, single oral dose
Study NCT01612143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: setrobuvir
Description: 200 mg tablet formulation, single oral dose
Study NCT00953719 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 36 mm ceramic head on a ceramic acetabular liner
Description: Total hip replacement with a 36 mm ceramic head on a ceramic liner
Study NCT00953719 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 28 mm ceramic head on a polyethylene acetabular liner
Description: Total hip replacement with a 28 mm ceramic head on a polyethylene liner.
Study NCT03248934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Self-Administered Diagnostic Exam
Description: Participants will complete a patient self-administered diagnostic exam. A physician will be available to monitor the patient and record findings but will not physically assist the participants.
Study NCT03248934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinician-Performed Diagnostic Exam
Description: A clinician-performed diagnostic exam will be completed on the patients.
Study NCT01182766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate with brief behavioral enhancement therapy
Description: high-dose topiramate (up to 250 mg/day), or low-dose topiramate (up to 125 mg/day)
Study NCT01182766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with brief behavioral enhancement therapy
Description: placebo
Study NCT03027557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet 30 mg Tablet
Description: Participants in one arm will receive 30 mg cinacalcet each day.
Study NCT03027557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab Inj 60 mg/ml
Description: Participants in two arms will receive 60 mg Denosumab biannually.
Study NCT03027557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab Inj 60 mg/ml
Description: Participants in two arms will receive 60 mg Denosumab biannually.
Study NCT03027557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablets
Description: Participants in two arms will receive one placebo-tablet each day.
Study NCT03027557 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Participants in two arms will receive one placebo-tablet each day.
Study NCT03027557 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection (Placebo)
Description: Participants in one arm will receive saline injections as placebo for denosumab.
Study NCT01478360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 (secukinumab)
Description: Secukinumab intravenous injection
Study NCT01478360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous injection
Study NCT01812889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOL-463 Vaginal ovule
Description: TOL-463 Vaginal Ovule
Study NCT01812889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOL-463 Vaginal gel
Description: TOL-463 Vaginal Gel
Study NCT03123250 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquablation
Description: The procedure is performed with the AquaBeam System. It is designed to utilize a high-velocity sterile saline waterjet as the cutting medium, which is projected through a nozzle positioned within the prostatic urethra. The Aquablation procedure integrates real-time ultrasound imaging with a robotically executed surgeon guided high-velocity waterjet to resect prostate tissue.
Study NCT00932685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 0.5mg/kg
Study NCT00932685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Game Boy
Description: Children given video game as a distraction in preop holding and were permitted to continue playing the game in OR during induction
Study NCT02033603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 30mls of 0.5% ropivacaine
Study NCT01205997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
Study NCT01205997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo(distilled water)
Description: Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
Study NCT04154904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will be randomized to complete either aerobic, high intensity interval training, or resistance exercise videos twice weekly at home.
Study NCT00753506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Artemisinin
Description: 100 mg of artemisinin twice per day for 10 weeks
Study NCT00753506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Identical looking placebo capsule
Description: Identical looking placebo twice per day for 10 weeks
Study NCT01840241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate
Description: BIVON group were received 0.5 mmol/kg of sodium bicarbonate for 1hours after induction of anesthesia and following 0.15 mmol/kg of sodium bicarbonate during the operation.
Study NCT01840241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study NCT03193502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: rivaroxaban
Study NCT04605172 — intervention group
Intervention type: OTHER
Intervention: hospitalization for premature birth
Description: Number of inborn and outborn infants prematurely born during a specific period of time